-
Active Stocks to Watch: ImmunoGen (NASDAQ:IMGN), Repligen Corporation (NASDAQ:RGEN), AT&T (NYSE:T), AeroVironment (NASDAQ:AVAV), TherapeuticsMD (NYSEMKT:TXMD)
On Friday shares of ImmunoGen, Inc. (NASDAQ:IMGN) closed at $8.25. Company’s sales growth for last 5 years was 16.40%.On March 20, 2015, ImmunoGen, Inc. (NASDAQ:IMGN) entered into a right-to-test agreement with Takeda Pharmaceutical Company Limited through its wholly owned subsidiary, Millennium Pharmaceuticals, Inc. The agreement provides Takeda with the right to (a) take exclusive options,…
-
Trader’s Alert: Trevena (NASDAQ:TRVN), TherapeuticsMD (NYSEMKT:TXMD), Landstar System Inc. (NASDAQ:LSTR), Allison Transmission Holdings (NYSE:ALSN)
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, announced that it will host a conference call on Wednesday, March 18, 2015 at 8:30 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2014. On Thursday shares of Trevena, Inc. (NASDAQ:TRVN) closed at $6.25. On March 10, TherapeuticsMD,…
-
Market Watch: TherapeuticsMD (NYSEMKT:TXMD), BioCryst Pharmaceuticals (NASDAQ:BCRX), Lazard (NYSE:LAZ), Entertainment Gaming Asia Inc. (NASDAQ:EGT), Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
TherapeuticsMD, Inc. (NYSEMKT:TXMD) declared its fourth quarter and full-year financial results for the period ending Dec. 31, 2014. Net proceed raised to about $15.0 million in 2014 contrast with about $8.8 million in the preceding year, reflecting a 71 percent raise in product sales. On Thursday shares of TherapeuticsMD, Inc. (NYSEMKT:TXMD) closed at $5.65. On…
-
Mix Sector Stocks News: Inuvo (NYSEMKT:INUV), TherapeuticsMD (NYSEMKT:TXMD), Archer-Daniels-Midland Company (NYSE:ADM), Providence Service Corp. (NASDAQ:PRSC), HEICO Corporation (NYSE:HEI)
Inuvo, Inc. (NYSEMKT:INUV) announced that management of the Company will participate in the 27th Annual Roth Conference being held on March 8-11, 2015 at the Ritz Carlton Hotel, in Dana Point, CA. On Thursday shares of Inuvo, Inc. (NYSEMKT:INUV) closed at $1.34. Company’s sales growth for last 5 years was 4.50% and EPS growth for…
-
Stocks News Alert: Alcatel Lucent SA (ADR) (NYSE:ALU), TherapeuticsMD (NYSEMKT:TXMD), Noodles & Company (NASDAQ:NDLS), GTX Inc. (NASDAQ:GTXI), 21Vianet Group (NASDAQ:VNET)
Zacks upgraded shares of Alcatel Lucent SA (NYSE:ALU) from a neutral rating to an outperform rating in a research report sent to investors on Friday morning. The firm currently has $4.75 price target on the stock. On Friday shares of Alcatel Lucent SA (ADR) (NYSE:ALU) closed at $3.89. Company’s sales growth for last 5 years…
-
Don’t Miss These Stocks: Pfizer Inc. (NYSE:PFE), TherapeuticsMD (NYSEMKT:TXMD), CSG Systems International Inc. (NASDAQ:CSGS), Mohawk Industries Inc. (NYSE:MHK), Ford Motor (NYSE:F)
Pfizer Inc. (NYSE:PFE) will buy back $5 billion of its stock under an agreement with Goldman Sachs. The drugmaker said Monday the accelerated stock buyback is part of its $11 billion share repurchase plan authorized in October. It said it will receive the approximately 150 million shares involved in the buyback from Goldman Sachs on…
-
Ever Green Stocks: Advaxis (NASDAQ:ADXS), Pfizer Inc. (NYSE:PFE), TherapeuticsMD (NYSEMKT:TXMD), GP Strategies Corp. (NYSE:GPX), iCAD (NASDAQ:ICAD)
Advaxis, Inc. (NASDAQ:ADXS), has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). On Wednesday shares of Advaxis, Inc. (NASDAQ:ADXS) closed at $7.46. Pfizer Inc. (NYSE:PFE) announced that it has entered…
-
Stocks in Focus: Anthera Pharmaceuticals (NASDAQ:ANTH), SouFun (NYSE:SFUN), TherapeuticsMD (NYSEMKT:TXMD), Arthur J Gallagher (NYSE:AJG), American Electric Power (NYSE:AEP)
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) announced the successful completion of an interim analysis of its Phase 3 trial (CHABLIS-SC1) of blisibimod in patients with Systemic Lupus Erythematosus and that the study should continue to completion as planned. An independent statistician conducted the interim futility analysis for the CHABLIS-SC1 study, evaluating the SRI-6 response at the 24…
-
Investors Are Eying: TherapeuticsMD (NYSEMKT:TXMD), Midstates Petroleum Company (NYSE:MPO), Willis Group Holdings PLC (NYSE:WSH), Cal-Maine Foods (NASDAQ:CALM), Theravance Biopharma (NASDAQ:TBPH)
TherapeuticsMD, Inc. (NYSE MKT:TXMD) announced the launch of an underwritten public offering of shares of its common stock. TherapeuticsMD also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock to cover overallotments, if any. All of the shares in the offering are to…
-
Traders Should Watch: Energy XXI Ltd (NASDAQ:EXXI), Molina Healthcare (NYSE:MOH), TherapeuticsMD (NYSEMKT:TXMD), Camtek (NASDAQ:CAMT), The Sherwin-Williams Company (NYSE:SHW)
Energy XXI Ltd. (NASDAQ:EXXI) reported a fiscal second-quarter loss of $373.9 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Hamilton, Bermuda-based company said it had a loss of $4.01. Losses, adjusted for non-recurring costs, came to 35 cents per share. On Tuesday shares of Energy XXI…